Eli Lilly is no longer just selling the market on obesity demand; it is proving that reimbursement is finally starting to catch up. That matters more than another splashy trial headline because paid access is what turns interest into durable volume. The stock's 7.0% jump and push toward a new 52-week high fit that shift in narrative, but the real catalyst is the expected July 1 Medicare access for Zepbound layered on top of expanding PBM coverage. At this point, the bull case is not that obesity is a big market; it is that Lilly is getting more of that market paid for.
The cleanest reason to stay bullish is that access is broadening at the same time the core business is already compounding at an elite rate. Lilly said all three of the largest PBMs would cover its full obesity portfolio, with CVS Caremark starting Foundayo coverage on June 1 and resuming broader Zepbound coverage by October 1. That lands on top of expected Medicare access for Zepbound by July 1, which is exactly the kind of reimbursement bridge this story needed. When a company is already growing revenue 44.7% year over year, better coverage is not a theoretical tailwind; it is a direct accelerant.
The second reason the setup still works is that Lilly is not buying growth with weak economics. Gross margin sits at 83.5%, operating margin at 45.9%, and net margin at 35.0%, which is a different class of profitability than most large-cap pharma peers. That operating profile helps explain why the TickerSpark Score is 85 overall, with perfect 100 scores in Profitability, Growth, and Momentum. Investors are paying up at 42.78 times trailing earnings, but they are paying for a business that is converting category leadership into real earnings power, with EPS up 95.6% year over year.
The quality of execution also keeps showing up in the tape and in results. Lilly has beaten earnings in five of the last seven reported quarters, including a 25.9% beat on April 30, and management raised full-year guidance after that report. Technically, the stock is acting exactly like a leader should: it is trading above its 20-day, 50-day, and 200-day averages, sits just below its 52-week high of $1,215.76, and market data shows an accumulation trend in volume. Against a healthcare sector up just 3.1% year to date, Lilly is up 11.8%, which says this is not just a defensive sector bid; it is company-specific leadership.
The pushback is real, and it is not hard to find. Cigna is dropping GLP-1 obesity coverage for its own employees effective July 1, and some employers are already signaling they may pull back in 2027 as utilization rises. That is the most credible knock on the stock: coverage expansion is uneven, and not every payer is ready to absorb the cost curve.
The other obvious complaint is valuation. Lilly trades at 15.73 times sales and 35.09 times EV/EBITDA, far richer than peers like JNJ, AZN, ABBV, or NVS, and recent insider activity shows two sells totaling 16,120 shares worth $16.43 million. Even so, that argument loses force when the business is growing revenue nearly 45% and net income 94.9% year over year while consensus still sits at Buy with 33 buys against 9 holds and 3 sells. Expensive stocks stay expensive when the market realizes the earnings runway is getting shorter to monetize, not longer.
That leaves Lilly looking like a stock to own on execution, not a stock to fade on sticker shock. We would stay constructive as long as the reimbursement story keeps translating into prescription and guidance follow-through, with the next hard checkpoints being the July 1 Medicare access start, the October 1 broader CVS coverage expansion, and the next earnings report. If those milestones confirm that access is converting into paid demand, the premium multiple remains justified.
The risk management point is simple: this is not a sleepy pharma name, and the RSI at 72.35 says the stock is extended in the near term. We would respect that and avoid treating LLY like a low-volatility value holding. Still, unless access momentum stalls or management stops converting it into growth, the path of least resistance remains higher because Lilly is turning obesity demand into reimbursement-backed revenue.
